Broncus IPO: Thoughts on First Day Trading
Though Broncus priced its IPO at the top-end of its price range, our reverse DCF model suggests that Broncus’ IPO is overvalued. We expect shares...
385 Views
Broncus (堃博医疗) IPO Trading: Chilled for a Reason but Mind the Share Concentration
We look at the updates since our last note for Broncus IPO. We re-iterate our view that the company is fairly valued at the top end and will stay...
332 Views
ECM Weekly (19th September 2021) - PHC, StarHealth, TDCX, Biel Crystal, DRCBank, Transcenta, Broncus
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
396 Views
Broncus IPO Valuation: Overly Ambitious
Our reverse DCF suggests that the revenues need to grow at a CAGR of 86.3% in order to justify the implied IPO valuation of HK$7.68bn which seems...
320 Views
Broncus (堃博医疗) IPO: Long Term Faith Needed
We provide an update for the book building of Broncus. The company has an interesting product portfolio but the sales ramp-up will be slow.
289 Views